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Summary: Due to the current COVID-19 pandemic, worldwide population’s lifestyle has changed dra-
matically, causing psychosocial consequences.  Patients presenting a preexisting chronic condition, as Type 1 
Diabetes (T1D), are the ones suffering the most from this situation. Moreover, people affected by diabetes are 
the ones with the worst prognosis, if infected by SARS-CoV-2.  We analyzed why patients with T1D were 
poorly represented between the subjects hospitalized for COVID-19 and why the cases of diabetic ketoaci-
dosis (DKA) were fewer and more severe compared with the past years. Furthermore, literature has showed 
how patients of all ages with T1D did not experience a deterioration in their glucose control throughout the 
lockdown. Among other causes, this is also due to the surging use of telemedicine. Finally, we tried to un-
derstand how the coronavirus tropism for endocrine tissues could influence the future epidemiology of T1D, 
focusing on the effects they have on pancreatic β-cells. 
Key words: COVID19, Type 1 Diabetes, Children, Telemedicine
Background
In December 2019 in Wuhan, Hubei province, 
China, a new infection disease began to spread: Cor-
onavirus Disease 2019 (COVID-19). The disease, 
caused by the Severe Acute Respiratory Syndrome 
CoronaVirus 2 (SARS-CoV-2), rapidly increased 
worldwide, causing thousands of deaths.
The World Health Organization declared the 
outbreak a Public Health Emergency of International 
Concern on January 30, 2020 (1), and a pandemic on 
March 11, 2020 (2).
The clinical picture of the infection has an ex-
treme variability: it goes from asymptomatic patients 
or mild forms with fever, cough, fatigue, and loss of 
smell and taste, to severe cases ending up in ICU for an 
Acute Respiratory Distress Syndrome (ARDS). This 
is due to a ripple effect caused by a cytokine storm 
that may lead to multi-organ failure, septic shock, or 
thrombosis. Since the beginning of the pandemic, 
COVID-19 caused a significant concern for the pos-
sible consequences in patients presenting a preexisting 
chronic condition, such as diabetes (3). Moreover, the 
pandemic was a major challenge to both diagnosis and 
treatment at the onset and in the follow-up of Type 1 
Diabetes (T1D).
In this short review, we update the relevant con-
cerns and challenges of COVID-19 in T1D patients, 
namely in children and adolescents.
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Methods
A literature search was conducted using PubMed. 
The terms used were COVID-19 OR coronavirus 
AND Type 1 Diabetes and as filter all articles about 
pediatric and adolescent population were included. 
Most of the publications were single case reports, 
small case series, original articles, letters or literature 
reviews.
Do All Patients With Diabetes are at Risk for 
COVID-19?
The epidemiological studies clearly show that 
the prevalence of subjects with diabetes affected by 
 COVID-19 is not different from the prevalence of 
diabetes in the general population (4-7). However, 
diabetes has been identified as an important risk fac-
tor for higher mortality and higher rate of progression 
to acute respiratory distress syndrome in hospitalized 
patients with COVID-19. In particular, the vast major-
ity of the more severe COVID-19 diabetic patients are 
adults  affected by type 2 diabetes. This is due to the pre- 
existence of micro and macrovascular complications (5). 
Patients with T1D are poorly represented among 
the subjects hospitalized for COVID-19 (5,6); how-
ever, this same demographic is way more represented 
in hospitalized cases than in the general population 
(1.5% vs 0.4% respectively) (7).  
This peculiarity brought to a series of hypotheses. 
For instance, this may be due to the lower prevalence of 
the COVID-19 among younger people, and to the fact 
that T1D is majorly present in younger individuals (8).
Moreover, the limited involvement of patients 
with T1D in this pandemic may be probably caused 
by their alertness to the evolving situation and the pre-
cautionary approach they had as carriers of a chronic 
condition (9).
Nevertheless, these hypotheses cannot fully ex-
plain the data since, as said by Tatti et al. (10), there 
are not comparative cases in a T1D adult population. 
Furthermore, the spreading of the virus mainly hap-
pened after several policies were applied by Italy and 
many other countries, ranging from social distancing 
measures to flights’ shutdown. 
On the other hand, it would be rather impor-
tant to focus on the genetic and immunological ba-
sis of autoimmune diabetes. First of all, because the 
subjects with T1D share a common genetic back-
ground. Secondly, the milder course of the disease 
in Type 1 Diabetes cases could be explained by an 
imbalance between Th1 and Th2 immunity (11). 
This immunological pattern causes insulitis in sub-
jects with TID. In fact, the Th1 immunity is mainly 
proinflammatory and acts against pathogens, inter-
nalizing them, and this may be the case of SARS-
CoV-2. 
This hypothesis could also explain why children 
and adolescents usually experience a milder course of 
the COVID-19 disease. In younger individuals, the 
prevalence of Th1 immunity is predominant against 
the Th2 immunity, which is mediated by B-lympho-
cytes and antibodies (12).
DKA in COVID-19 Pandemic
Diabetic ketoacidosis (DKA) is a common and 
potentially lethal acute onset scenario or a compli-
cation of diabetes caused by a relative or absolute 
 insulin deficiency. DKA occurs frequently in different 
 occasions: at the onset of the disease, when the patient 
misses the doses of insulin, or in the setting of another 
moderate to severe illness.
This process generates an inflammatory state 
(producing pro-inflammatory cytokines, IL-6, TNFα 
and IL-β) which can be sometimes accompanied by an 
underlying illness. 
Looking at previous research on coronaviruses, it 
has been demonstrated that SARS-CoV-1 binds the 
Angiotensin-Converting Enzyme 2 (ACE2) receptor 
in the pancreatic islets. The binding between the vi-
ruses and the receptors provokes a damage of the islets 
leading to acute diabetes (13). This happens also for 
SARS-CoV-2 (14).
Moreover, it is important to notice how COV-
ID-19 patients with a severe disease, have high levels 
of inflammatory markers such as IL-6. The inflam-
matory cascades of the two pathologies (COVID-19 
and T1D) may act synergistically leading to a worse 
outcome.
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The Italian Society for Pediatric Endocrinology 
and Diabetes (ISPED) evaluated the changing of fre-
quencies of DKA, clinical conditions at diagnosis, and 
acute complications in the early phase of COVID-19 
in people with T1D (15). Data show that, during the 
observation, the new onsets of T1D are less than those 
in the same period of 2019. On the other hand, chil-
dren with DKA presented a more severe form of DKA 
than in 2019. 
The decreased number of T1D onsets can be the 
result of the fear of COVID-19. A recent survey in 
Emilia-Romagna region (Italy) clearly showed a con-
sistent drop in attendances at the Pediatric Emergency 
Unit during the COVID-19 epidemic (16) increas-
ing the risk of delayed diagnoses of potentially severe 
disease, like T1D. Moreover, this is also caused by a 
lower exposure to seasonal viruses, since one of the first 
social distancing measures adopted by the Italian gov-
ernment concerned the shutdown of schools.
Furthermore, the possible delayed diagnosis of 
T1D could also explain the increase of severe DKA 
registered, alongside the effects of SARS-CoV-2 on 
β-cells (13).
A study by Ebekozien et al. (17) shows that DKA 
is the most prevalent adverse outcome in patients with 
COVID-19 disease, in addition to hyperglycemia. 
Moreover, COVID-19 symptoms can mask the onset 
of DKA (18) delaying the diagnosis.
As a final consideration, all data analyzed push to 
improve the prevention of DKA carrying out specific 
campaigns for parents and doctors, as it occurred in 
Italy with the help of the Scientific Societies and Pa-
tients Associations.
Glycemic Control in Adults and Children With 
Type 1 Diabetes During the Lockdown
During the pandemic, most countries issued strict 
governmental decrees that imposed social distancing 
and isolation to avoid and minimize community-based 
viral transmission. Indeed, the Italian government was 
one of the firsts to impose a lockdown restriction from 
March 9 to May 3, 2020 (19).  These measures gradu-
ally reduced the cases of infection but changed com-
pletely the lifestyle of the inhabitants.
The lockdown period and the change in lifestyle 
may have been affecting the psychosocial health of the 
population. In fact, those affected by a chronic illness 
presented a major risk (20): people affected by T1D 
were unable to continue their routinely follow-up and 
they were obliged to modify the management of their 
chronic disease.
Despite this unexpected change of lifestyle, all 
the studies published until now show that patients of 
all ages with T1D did not experience deterioration in 
their glucose control during lockdown.
Bonora et al. (21) analyzed a group of adult pa-
tients affected by T1D who was using a FGM system 
during the period of lockdown and the weeks before it. 
They observed that glucose control improved (increas-
ing the Time In Range and reducing average glucose) 
during the first week of lockdown. The authors empha-
sized that the slowdown of the routine activities has 
a favorable effect on glucose control. This is probably 
due to the more regular lifestyle, the more time com-
posing meals, and the risk awareness of more severe 
COVID-19 complications. Confirming this hypoth-
esis, the control group including patients who contin-
ued their work routine did not show an improvement 
in their glycemic control. 
Moreover, Schiaffini et al (22) analyzed a group 
of pre-school and school children that utilize a tan-
dem basal bolus IQ. This demographic showed a better 
metabolic performance improving the glycemic Time 
In Range, and reducing the glycemic Time Above 
Range. What probably makes the difference on the 
management of diabetes at this age is the shift to a 
full-time parental control: parents control more often 
glycemic levels, adapt insulin management, and pre-
pare meals in a more accurate way.
Adolescents also showed a good glycemic control 
at baseline, and they did not worsen during the first 
weeks of lockdown; improving the time in glycemic 
range and reducing the time below the range in the 
following weeks.  Furthermore, the period of lockdown 
had no pejorative effects on the metabolic control on 
this demographic. These results in adolescents are 
probably due to the exclusion of the influence played 
by some school and after-school activities, eating every 
meal at home, and in-home physical activities (23).
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Confirming this hypothesis, an Italian web-based 
pediatric survey analyzed the changing of lifestyle 
in patients with Type 1 Diabetes during the quaran-
tine period due to COVID-19 (24). It showed how 
>12-year-old patients reported having practiced in-
door physical activities regularly during the lockdown: 
regular exercise is fundamental even for psychologi-
cal wellbeing, since it reduces anxiety and it improves 
the general mood and the quality of sleep (25). While 
<12-year-old patients monitored glycemic levels more 
often, probably because of the higher parental control 
during the “stay at home” policy.
The Role of Telemedicine 
In this lockdown period, routinely medical activi-
ties were near totally reduced to enlarge the ICU ca-
pacity and minimize the social activities among people 
if not strictly necessary. People with a chronic illness 
would have been deprived by their follow-up check-
ups, if it were not for telemedicine.
Telemedicine offers a way to be close to patients 
with T1D, even during the pandemic, as physical 
proximity is not always necessary.
Nowadays technology plays an important role in 
diabetic management. A large percentage of patients 
with T1D and parents handle regularly continuous or 
fast glucose monitoring and the insulin pump. Most 
of the data collected by these instruments can be re-
motely analyzed by the doctor, who can suggest and 
discuss with the patient the management of the gly-
cemic control.
This new medical approach has been largely used 
during the pandemic with good results as reported 
above (21,23): even if the rapid improvement of tele-
medicine has been the only viable way in the pandemic, 
we think that it could be integrated in the business-as-
usual care of T1D in the aftermath. In fact, telemedi-
cine is more sustainable: it gives a better continuity of 
the assistance and healthcare; it fastens and simplifies 
the communication between doctors and patients.
Furthermore, also past years’ studies showed how 
telemedicine is a proven modality to prevent DKA 
in adolescents and an effective tool for diabetes care 
(26, 27). Moreover, at the onset of diabetes, the start 
of an insulin treatment and education should not 
be  postponed, so during the pandemic, when it was 
not possible to educate people in medical structures, 
 teleconferencing was a valid alternative. However, tel-
emedicine raises new issues, such as a privacy one (28). 
Can COVID-19 Change the Epidemiology of T1D?
It is known that viral infections have been widely 
associated with the T1D pathogenesis. In 2017, the 
TEDDY study (30) proved an increased risk of β-cells 
autoimmunity in a group of patients that recently ex-
perienced a respiratory infection caused by a range of 
different pathogens, including Coronavirus.
The mechanisms at the basis of the autoimmune 
insulitis are different: the amplification of viruses or the 
diffusion of viral antigens in the circulation can deter-
mine an immune response involving pancreatic cells; a 
direct damage of β-cells may release sequestered islet 
antigens; viral epitopes sharing homologies with au-
toantigens leading to the production of cross-reactive 
antibodies against β-cells; a viral infection promotes 
cytokine releasing and T-cell activation in individuals 
genetically predisposed to autoimmunity contributing 
to the faster development of diabetes (30).
Moreover, as anticipated, SARS-CoV-2 binds 
the ACE2 receptors, which are expressed in metabolic 
organs and tissues (pancreatic β-cells, adipose tissue, 
small intestine, and kidneys). Therefore, it is possible 
that the virus alters the glucose metabolism and that 
it could complicate the pathophysiology of preexisting 
diabetes or lead to new mechanisms of the disease and 
to an onset of diabetes (31).
So, given that T1D has already been related 
to coronavirus respiratory infections and knowing 
what happened after the SARS-CoV-1 pandemic 
in 2003, we can infer that something similar could 
happen in the future.  A recent case of a young 
woman developing an autoimmune T1D one month 
after getting affected by COVID-19 support this 
hypothesis (32).
It is plausible to presume that the pandemic 
will trigger an increase of T1D cases during the 
next months/years, especially in people infected by 
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SARS-CoV-2 that are genetically predisposed to 
diabetes (33).
Conclusions
COVID-19 pandemic continues to be a concern 
for doctors since it is well known it can be particular-
ly severe for T1D-patients, leading to a more compli-
cate scenario, increasing the mortality risk. Therefore, 
SARS-CoV-2 can impair also the DKA presenta-
tion. During the quarantine, the cases of DKA were 
less numerous, but more severe than the ones in the 
last years. 
However, the challenge in the management of 
the disease is successfully raising attention to the meal 
composition and improving the metabolic control due 
to the constant presence of parents during the day, par-
ticularly in the pre-school and school children. Even 
the adolescents, especially the ones who practice phys-
ical activity at home, demonstrated a better glycemic 
control.
Telemedicine was fundamental and probably sim-
plified the relationship between the doctor and the 
patient, bringing them closer. In addition, the “stay at 
home” policy brought light to the management of dia-
betes as a priority to tackle during the lockdown.
To conclude, the effects of the virus on the en-
docrine pancreatic tissue remain a pending issue. We 
cannot exclude a “second wave” of onsets of T1D due 
to the viral trigger of SARS-CoV-2.
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